Turn Therapeutics Reports GX-03 Skin Inflammation Research
Westlake Village, California, August 20, 2026 Turn Therapeutics announced new peer-reviewed research providing in-vivo evidence that GX-03 selectively reduces...
Dermatology
Advertisement
LEO Pharma Expands Dermatology Pipeline After H1 Growth
BALLERUP, Denmark — August 18, 2026 LEO Pharma reported continued momentum in its dermatology business during the first half...
Sagimet Biosciences Secures FDA Clearance for Acne Phase 3 Trial
FOSTER CITY, Calif., August 13, 2026 Sagimet Biosciences Inc. announced that the U.S. Food and Drug Administration (FDA) has...
Pfizer Reports Positive Phase 3 Results for LITFULO in Vitiligo
NEW YORK, July 30, 2026 Pfizer Inc. announced positive topline Phase 3 results for LITFULO™ (ritlecitinib) in patients with...
AbbVie Secures EU Approval for RINVOQ in Severe Alopecia Areata
NORTH CHICAGO, Ill., July 29, 2026 AbbVie announced that the European Commission (EC) has approved RINVOQ® (upadacitinib) for the...
Advertisements
AbbVie Gains EU Approval for RINVOQ in Vitiligo Care
North Chicago, Ill., July 29, 2026 AbbVie announced that the European Commission (EC) has approved RINVOQ® (upadacitinib) for the...
Incyte Secures EU Approval for Opzelura Cream in Atopic Dermatitis
WILMINGTON, Del., July 29, 2026 Incyte announced that the European Commission (EC) has approved Opzelura® (ruxolitinib) cream for the...
Medicus Pharma Receives FDA Clearance for Registrational SkinJect Study
PHILADELPHIA, July 27, 2026 Medicus Pharma Ltd. announced that the U.S. Food and Drug Administration (FDA) has issued a...
Organon Reports Positive Phase 3 VTAMA Data in Atopic Dermatitis
JERSEY CITY, N.J., July 24, 2026 Organon (NYSE: OGN) presented new post hoc pooled Phase 3 data from the...
Devonian Begins Pediatric Phase II/III Thykamine Trial
QUÉBEC, Canada, July 21, 2026 Devonian Health Group has received Health Canada authorization to initiate a Phase II/III clinical...
Advertisement
